Hematologist
CION Cancer Clinics
Is some GVHD actually good? | CION Cancer Clinics
The graft-versus-leukaemia effect is when donor immune cells from a transplant attack leukaemia cells left in your body. The same cells can cause GVHD, so mild GVHD often comes with this useful attack. Severe GVHD is still harmful, and the effect can work without any GVHD at all. This page explains how it works, how transplant teams use it, and what it cannot tell you. At CION Cancer Clinics, our haematology team assesses whether a transplant or CAR-T fits your situation and coordinates care with qualified centres.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Can GVHD really be a good thing?
- How do donor cells attack leukaemia?
- How are GVHD and the graft-versus-leukaemia effect different?
- How do transplant teams use this effect?
- What do families misunderstand about this effect?
- Which report words relate to this effect?
- What can this page not tell you?
- Common questions about the graft-versus-leukaemia effect
The short answer
Can GVHD really be a good thing?
Partly, yes. The donor immune cells that cause GVHD can also attack leukaemia cells left behind after treatment, and this is called the graft-versus-leukaemia effect. Mild GVHD often travels with that useful attack, but severe GVHD is never something to hope for.
Where the effect comes from
A donor transplant gives you a new immune system from another person. Its white cells, especially the T cells, check everything they meet. They treat your cells as foreign. When they turn on your skin, gut or liver, that is GVHD. When they turn on cancer cells, that is the graft-versus-leukaemia effect, sometimes written as GVL.
Why it matters to you
It is one of the main reasons a donor transplant can keep some blood cancers away when chemotherapy alone could not. The chemotherapy and radiation before transplant do part of the work. The donor cells keep doing the rest for months and years afterwards.
Who it does not apply to
A transplant using your own stem cells, called autologous, has no donor cells and no graft-versus-leukaemia effect. The effect is also weaker with an identical twin donor, because the twin's cells see very little as foreign.
Not every blood cancer responds to this effect to the same degree. Your haematologist can say how much it matters for your diagnosis.Step by step
How do donor cells attack leukaemia?
The old marrow is cleared
Chemotherapy, with or without radiation, lowers the number of cancer cells and makes room for the donor cells. It rarely removes every last cancer cell on its own.
Donor cells settle in
The donor stem cells travel to your bone marrow and start making new blood and immune cells. This is called engraftment.
The new immune cells patrol
Donor T cells look for markers on cells that differ from the donor's own. Leukaemia cells carry many of these markers, so they become targets.
The attack keeps going
Unlike chemotherapy, which stops when the course ends, the donor immune system keeps watching. That long watch is what helps hold the cancer back over time.
Not sure whether this applies to you?
Ask an oncologistSide by side
How are GVHD and the graft-versus-leukaemia effect different?
GVHD
Graft-versus-leukaemia effect
Donor cells attack healthy organs such as skin, gut and liver
Donor cells attack leftover leukaemia cells
You can see and feel it: rash, loose motions, yellow eyes
Silent: you feel nothing, it shows only on tests over time
Treated when it appears, often with steroids
Protected by lowering medicines carefully, never rushing
Severe forms are dangerous and need urgent care
Helps lower the chance of the cancer coming back
In practice
How do transplant teams use this effect?
Your team is always balancing two risks: too much immune attack on your body, and too little on the cancer.
Not over-calming the immune system
GVHD prevention medicines are strong enough to protect you, but the team avoids more than you need, so the donor cells can still do their job against the cancer.
Lowering medicines when relapse is a worry
If tests suggest the cancer may be returning, the team may lower immune-calming medicines sooner, to let the donor cells act more strongly. This is their decision, never a home change.
Donor lymphocyte infusion
Extra immune cells from the same donor, given through a drip, to boost the attack on the cancer. It can also bring on GVHD.
Sometimes considered when
- Cancer returns after transplant
- Donor cells are losing ground on tests
Gentler transplants
Reduced-intensity transplants use milder chemotherapy and rely more on the donor cells to control the cancer. They may suit older or less fit people.
Commonly believed
What do families misunderstand about this effect?
"She has GVHD, so the leukaemia cannot come back."
GVHD suggests the donor cells are active, but it does not promise the cancer stays away. Relapse can still happen, and follow-up tests stay just as important.
"No GVHD means the transplant is not working."
Many people have little or no GVHD and still do well. The graft-versus-leukaemia effect can work quietly without any visible GVHD. No GVHD is not a reason to worry on its own.
"We should stop the GVHD medicines so the donor cells fight harder."
Stopping medicines at home can trigger severe GVHD, which can be life-threatening. Any change to the balance is planned by the transplant team with close monitoring.
"Treating GVHD will switch off the protection against cancer."
Treatment calms the immune system for a while, and teams weigh that carefully. Untreated severe GVHD is the bigger danger. The aim is to settle it and then bring medicines down slowly.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
On your report
Which report words relate to this effect?
- Chimerism
- A test showing how much of your blood comes from the donor. "Full donor chimerism" means nearly all of it does.
- Mixed chimerism
- Some of your own blood cells are still present alongside the donor's. The team watches whether this changes over time.
- MRD
- Minimal residual disease: very small amounts of cancer found only by sensitive tests, not by a normal blood count.
- DLI
- Donor lymphocyte infusion, extra donor immune cells given to strengthen the attack on the cancer.
- Relapse
- The cancer coming back after a period when it could not be found.
- Allogeneic
- A transplant using cells from a donor rather than your own.
Being straight with you
What can this page not tell you?
This page cannot tell you how strong the graft-versus-leukaemia effect is in your case, or what your outlook is. That depends on the type of blood cancer, how much was left before transplant, your donor, and your tests after transplant. Only your transplant team has all of that.
Why a rash is not good news or bad news on its own
Families sometimes feel relief when GVHD appears, or panic when it does not. Neither reaction fits. A new rash, loose motions or yellowing of the eyes still needs a same-day call to the transplant team, whatever it might mean for the cancer.
Questions worth asking
How much does this effect matter for my type of cancer? What do my chimerism and MRD results show? What would you do if tests suggest relapse? Is a donor lymphocyte infusion ever an option for me?
Where CION fits
CION does not carry out transplants. Our haematology team can read your reports with you, discuss your case at a tumour board and help you prepare for conversations with your transplant centre.
Questions we are asked
Common questions about the graft-versus-leukaemia effect
Is the graft-versus-leukaemia effect the same as GVHD?
No, but they come from the same donor immune cells. GVHD is the attack on your healthy organs. The graft-versus-leukaemia effect is the attack on cancer cells. They often appear together, which is why doctors try to limit GVHD without shutting down the donor immune system completely.
Does it work for lymphoma and myeloma too?
A similar donor attack can act against some lymphomas, myeloma and other blood cancers, and is sometimes called a graft-versus-tumour effect. How strong it is varies a lot between diseases. Your haematologist can explain how much it counts for your own diagnosis.
Should I want to get some GVHD?
No. You cannot choose how mild or severe GVHD will be, and severe GVHD can be very harmful. The effect against leukaemia can happen without visible GVHD. Leave the balance to your transplant team and report symptoms promptly rather than waiting to see.
What is a donor lymphocyte infusion like?
It is usually given through a drip, much like a blood transfusion, often as a day-care visit. The donor gives immune cells from their blood. Afterwards, you are watched closely for GVHD and for low blood counts. It is not suitable for everyone, and your team decides if it fits.
Why does my team keep checking chimerism?
Chimerism shows whether donor cells are holding their place in your marrow. If your own cells start to return, it can be an early sign of trouble, sometimes before relapse shows on other tests. That gives the team a chance to act, for example by adjusting medicines.
If the cancer comes back, is another transplant the only option?
Not always. Depending on the situation, options may include lowering immune-calming medicines, donor lymphocyte infusion, targeted medicines, chemotherapy or a clinical trial. Some people are offered a second transplant. The choice depends on timing, fitness and disease type.
Does a better-matched donor give a stronger effect?
Not simply. A closer match usually means less GVHD, while a less close match may bring more of both GVHD and the attack on cancer. Teams choose donors on many factors, and modern medicines have narrowed these differences. Ask your team why they chose your donor.
Can CION arrange a transplant?
CION does not carry out transplants in-house. Our haematology team can review your case, present it at a tumour board and coordinate care and referral with qualified transplant centres. Ask about schemes such as Aarogyasri, CGHS, ECHS, EHS, PM-JAY or cashless insurance, and check their current rules.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Patient stories
Hear it from people we have treated
Every story is a video, in the patient's own words. Nothing here is a written testimonial.
Sources
- National Cancer Institute — Stem Cell Transplants in Cancer Treatment
- Leukemia & Lymphoma Society — Graft-Versus-Host Disease
- Cancer.Net — Graft-Versus-Host Disease
- NHS — Stem cell and bone marrow transplants
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
GVHD Explained: When the New Immune System AttacksThe basics of GVHD itselfPreventing GVHD in the First PlaceHow prevention is balanced against this effectTapering Immunosuppression After TransplantHow medicines are lowered and why it takes timeLeukaemia guideThe blood cancer this effect is named afterGraft-versus-Host DiseaseEvery GVHD guide in one place
Talk to us
Want your transplant reports explained?
Tell us what has been found so far. Our haematology team will review your reports and help you plan questions for your transplant centre.